ARS Pharmaceuticals Inc. Common Stock SPRY · Stock Open ARS Pharmaceuticals Inc. Common Stock in new tab
ARS Pharmaceuticals Inc. Common Stock Analysis (SPRY)
Is ARS Pharmaceuticals Inc. Common Stock a good investment? ARS Pharmaceuticals Inc. Common Stock (SPRY) is currently trading at 10.48 USD. Market analysts have a consensus price target of 26.50 USD. This suggests a potential upside from current levels.
Earnings Schedule: ARS Pharmaceuticals Inc. Common Stock is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -0.76.
Investor FAQ
Does ARS Pharmaceuticals Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is ARS Pharmaceuticals Inc. Common Stock?
ARS Pharmaceuticals Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -0.50.
Company Profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Community Discussion